Table 1 Outcome measures by RE-AIM category
Domain | Source | Months* collected |
|---|---|---|
Reach: # and % of patients excluded vs. participating (incl. characteristics) | EHR | 1–21 |
Effectiveness: prescriber averages of MME dose per day per opioid patient over the past 3 months (primary outcome) | EHR | 1–21 |
# and % of patients completing urine drug testing (past 12 months) | EHR | 1–21 |
# and % of patients screened for mental health using PHQ-2 (past 12 months) | EHR | 1–21 |
Mental health (PHQ-9) scores for patients screening positive on PHQ-2 (past 12 months) | EHR | 1–21 |
Overall rate and dose of opioid-benzodiazepine co-prescribing | EHR | 1–21 |
# and % of patients with treatment agreements (past 12 months) | EHR | 1–21 |
# and % of opioid prescriptions above 90 MME | EHR | 1–21 |
Patient attendance at scheduled clinic visits | EHR | 1–21 |
# and % of patients prescribed buprenorphine | EHR | 1–21 |
# and % of patients with PEG-3 score (past 12 months) | EHR | 1–21 |
PEG-3 scores (past 12 months) | EHR | 1–21 |
Adoption (setting): # and % of participating clinics vs. all clinics (incl. characteristics) | Health system | 1–21 |
Adoption (staff): # and % of participating staff vs. all eligible clinic staff (incl. characteristics) | Clinic | 1–21 |
Clinician attendance at intervention meetings | Research team | 1–21 |
Implementation: Hours of intervention received per clinic and prescriber | Research team | 1–21 |
Adaptations made to protocols during intervention period | Research team | 1–21 |
Assessment of moderators: clinic-level experience in QI, size of clinic (# patients), # and % of patients at the clinic on opioid doses > 90 MME | Research team, EHR | 0, 3, 9, 21 |
Qualitative assessment of mechanisms of action and factors influencing implementation | Research team | 1–21 |
Cost of each implementation sequence and combination | Research team | 1–21 |
Maintenance: 6-month follow-up on all effectiveness outcomes | EHR | 22–27 |